Amisulpride (Solian)
What studies of Amisulpride (Solian) found
At a glance, by condition
ME/CFS: B May help
Based on the strongest evidence, the randomised trial (low certainty), for overall symptoms.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Amisulpride (Solian) may help for ME/CFS, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- Amisulpride (Solian) · ME/CFS is hereBMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Fatigue1 study · 40 people took Amisulpride (Solian) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 1.92 (large).
The randomised trial40 randomised · 12 weeks · 25 mg, bid
Fatigue improved more than in the comparison group.
The evidence is very uncertain about the effect of amisulpride (Solian) on fatigue in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (40 in all)
- Effect size 1.92 (large)
How big was the difference?
1.92, large. The effect size compares Amisulpride (Solian) with fluoxetine group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 25 mg, bid
- Outcome
- FSS Krupp Fatigue Severity Scale
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Pain1 study · 40 people took Amisulpride (Solian) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 1.25 (large).
The randomised trial40 randomised · 12 weeks · 25 mg, bid
Pain improved more than in the comparison group.
The evidence is very uncertain about the effect of amisulpride (Solian) on pain in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (40 in all)
- Effect size 1.25 (large)
How big was the difference?
1.25, large. The effect size compares Amisulpride (Solian) with fluoxetine group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 25 mg, bid
- Outcome
- VAS-pain visual analog scale
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Low mood or anxiety1 study · 40 people took Amisulpride (Solian) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out; effect size 0.23 (small).
The randomised trial40 randomised · 12 weeks · 25 mg, bid
No clear difference in low mood or anxiety.
The evidence is very uncertain about the effect of amisulpride (Solian) on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 40 people found no clear difference; a small benefit can't be ruled out
- Effect size 0.23 (small)
How big was the difference?
0.23, small. The effect size compares Amisulpride (Solian) with fluoxetine group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 25 mg, bid
- Outcome
- HADS-D Hospital Anxiety and Depression Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Daily life and health overall
Overall symptoms1 study · 40 people took Amisulpride (Solian) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (40 in all); effect size 1.63 (large).
The randomised trial40 randomised · 12 weeks · 25 mg, bid
Overall symptoms improved more than in the comparison group.
Amisulpride (Solian) may improve overall symptoms in ME/CFS. Improvement · low certainty B
- Some concerns about bias (RoB 2)
- Few people (40 in all)
- Effect size 1.63 (large)
How big was the difference?
1.63, large. The effect size compares Amisulpride (Solian) with fluoxetine group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 25 mg, bid
- Outcome
- CGI-S Clinical Global Impression Severity
- Effect
- better
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Quality of life1 study · 40 people took Amisulpride (Solian) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 2.62 (large).
The randomised trial40 randomised · 12 weeks · 25 mg, bid
Quality of life improved more than in the comparison group.
The evidence is very uncertain about the effect of amisulpride (Solian) on quality of life in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (40 in all)
- Effect size 2.62 (large)
How big was the difference?
2.62, large. The effect size compares Amisulpride (Solian) with fluoxetine group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 25 mg, bid
- Outcome
- SF-12 Short-Form 12-Item Health Survey
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Side effects
Stopping because of side effects1 study
All the subjects completed the planned 12-week long therapy period
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
25 mg at the start
- 2Top dose
Most often 25 mg (1 of 1 studies)
Doses across 1 study
25 to 25 mg.
Each study’s dose, as printed
All papers
- Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study.2011 · randomised trial · 40 randomised
Summary
This pilot study asked whether low-dose amisulpride would improve symptoms in non-depressed chronic fatigue syndrome (CFS) compared with an SSRI. Forty patients at a single centre, enrolled through clinician referrals and self-referrals, were randomised to amisulpride 25 mg bid. or fluoxetine 20 mg uid. for twelve weeks; all subjects completed the planned 12-week therapy period and were un-blinded to treatment. Fatigue (Krupp Fatigue Severity Scale, FSS), anxiety and depression (HADS), pain and bodily discomfort (VAS-pain), quality of life (SF-12) and clinician-rated severity (CGI-S) were assessed at enrolment and after twelve weeks; side effects were assessed with FIBSER at twelve weeks. After twelve weeks, amisulpride-treated patients had lower FSS scores (36.3 ± 8.6 vs. 48.9 ± 4.9; p = 0.001), lower VAS-pain scores (40.5 ± 13.1 vs. 53.1 ± 8.3; p = 0.01), higher SF-12 scores (53.2 ± 4.8 vs. 37.6 ± 4.9; p = 0.01) and lower CGI-S scores (2.9 ± 0.6 vs. 4.2 ± 1.1; p = 0.005) than fluoxetine-treated patients. HADS-D (4.1 ± 0.9 vs. 4.3 ± 0.9; p = 0.6) and HADS-A (4.5 ± 1.0 vs. 4.9 ± 1.0; p = 0.6) did not differ between groups. Within the amisulpride group, FSS, VAS-pain, CGI-S and SF-12 changed significantly (p = 0.001 for each), while HADS-A (p = 0.14) and HADS-D (p = 0.1) did not. Within the fluoxetine group, HADS-D fell significantly (p = 0.009); FSS (p = 0.1), VAS-pain (p = 0.09), CGI-S (p = 0.1), SF-12 (p = 0.1) and HADS-A (p = 0.8) did not change significantly. FIBSER frequency, intensity and burden did not differ between groups (p = 0.6, p = 0.9, p = 0.6), and both drugs were equally well tolerated.